Levetiracetam

Levetiracetam is prescribed to treat:

• Epilepsy and seizures • Various related conditions in the neurological category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Levetiracetam (Keppra) is an antiseizure medication used for focal and generalised seizures, including myoclonic seizures and juvenile myoclonic epilepsy. It has become one of the most widely used antiepileptics, largely because of what it does not do: it has almost no drug interactions, requires no blood level monitoring, and can be started at an effective dose without slow titration.

Mechanism of Action

Levetiracetam binds synaptic vesicle protein 2A, a membrane glycoprotein involved in neurotransmitter vesicle release. This mechanism is unique among antiseizure drugs — it does not act on sodium channels, calcium channels, or GABA receptors, the targets of essentially every older agent.

Binding SV2A appears to modulate neurotransmitter release in a way that suppresses hypersynchronous firing without broadly depressing normal neural activity. The practical consequence is a favourable cognitive profile relative to older drugs, and a mechanism that does not overlap with other agents — which makes levetiracetam a rational partner in combination therapy when one drug is insufficient.

Its pharmacokinetics are unusually simple. Levetiracetam is not metabolised by cytochrome P450 enzymes and is cleared largely unchanged by the kidneys. It does not induce or inhibit hepatic enzymes, so it does not alter levels of warfarin, oral contraceptives, or the other drugs that older antiepileptics such as phenytoin and carbamazepine disturb.

That property is a significant part of its appeal. In a patient on multiple medications, in a woman of reproductive age relying on hormonal contraception, or in someone on anticoagulation, an antiseizure drug with no interactions removes a whole category of problem.

Behavioural Effects

The main limitation of levetiracetam is behavioural, and it is common enough that patients should be warned before starting.

Irritability, agitation, aggression, anxiety, mood lability, and depression occur in a meaningful minority — often described as a short fuse or an uncharacteristic temper. In children this presents as behavioural change at school or home; in adults, as strained relationships and unexplained anger.

These effects are frequently attributed to something else. A patient recently diagnosed with epilepsy has plenty of legitimate reasons for low mood and stress, so a drug effect is easy to miss, and families may not connect a personality change to a seizure medication at all. Asking directly at follow-up, and asking a family member as well as the patient, detects it more reliably than an open question.

The effects are dose-related and reverse on stopping. Pyridoxine supplementation is sometimes used and helps some patients. Where they persist, brivaracetam — which acts on the same target with a somewhat different profile — or a different class is the alternative. Our neurologic team manages these decisions, and the Epilepsy Foundation provides patient-level background.

Suicidal ideation carries a class warning applying to all antiseizure medications, and warrants specific enquiry.

Clinical Use

Levetiracetam is used as monotherapy and as adjunctive therapy across seizure types. Its broad spectrum — effective in both focal and generalised epilepsy — is an advantage when the seizure type is not yet fully characterised, since some drugs effective in focal epilepsy worsen generalised seizures.

It can be started at a therapeutic dose without the weeks of titration that lamotrigine requires, which matters when seizures need controlling quickly. An intravenous formulation allows straightforward switching in hospital.

Adherence is the central issue in epilepsy management, more than drug selection. Missed doses are the most common precipitant of breakthrough seizures, and the consequences — injury, loss of driving privileges, status epilepticus — are substantial. Simple regimens, once- or twice-daily dosing where possible, and honest conversation about what gets in the way are worth more than fine-tuning between agents.

Driving regulations after a seizure vary by state and are a practical matter patients need clear information about rather than vague reassurance.

Monitoring and Follow-Up

Levetiracetam requires no routine blood level monitoring, unlike phenytoin, carbamazepine, and valproate. Levels can be measured but rarely change management, and treatment is guided by seizure control and side effects.

Kidney function should be checked, since clearance is renal and dose reduction is required as eGFR falls. Patients on dialysis need supplemental dosing after sessions.

The monitoring that matters is behavioural and clinical: seizure frequency and type, mood and behaviour, and cognitive function. A seizure diary is more reliable than recall, particularly for brief events the patient may not be aware of.

Antiseizure medication should never be stopped abruptly, since withdrawal can precipitate seizures including status epilepticus. Any change is made by gradual taper with a plan. The MedlinePlus levetiracetam entry covers prescribing detail.

Special Populations

In pregnancy, levetiracetam is among the preferred antiseizure medications, with a comparatively reassuring malformation profile — considerably better than valproate, which carries substantial teratogenic and neurodevelopmental risk and should be avoided in women of childbearing potential wherever an alternative exists. Levels fall during pregnancy because clearance increases, so dose adjustment and monitoring are usually needed. Folic acid supplementation is standard before conception.

In older adults, kidney function declines with age and dose reduction is frequently needed; behavioural effects and falls warrant attention. In children it is widely used, with behavioural effects a particular consideration.

Uncontrolled seizures carry their own substantial risk in pregnancy, so stopping medication on discovering pregnancy is generally the wrong decision and should not be done without discussion.

When to Contact Your Doctor

Report irritability, aggression, marked mood change, anxiety, or depression — in yourself or as observed by family — since these are common, dose-related, and reversible, and there are alternatives. Report any thought of self-harm promptly.

Report breakthrough seizures, a change in seizure type or frequency, or any seizure lasting more than five minutes, which is a medical emergency. Report marked drowsiness, unsteadiness, or confusion, which may indicate accumulation if kidney function has changed.

Never stop levetiracetam abruptly. If you are pregnant or planning pregnancy, discuss it rather than stopping the medication, and expect that the dose may need increasing as pregnancy progresses.

To review seizure control, address behavioural side effects, or plan for pregnancy, contact us or schedule a visit.